Instrument NamePfizer IncInstrument Symbol(PFE-N)

Instrument ExchangeNYSE

Bargain hunters should love these great stocks.

/CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus...

After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement.

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

Cancer, a complex disease characterized by uncontrolled cell growth and proliferation, is often rooted in defects within DNA repair mechanisms. Normally, cells possess intricate repair pathways that rectify mutations or damage caused by environmental factors or internal processes. However, when these pathways malfunction, either due to genetics or acquired mutations,...

Telemedicine once seemed like it was going to revolutionize healthcare.

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Global Markets Canadian Markets: Canada’s TSX stock rose on a increase in the oil price, while the Trudeau government added new mortgage rules to win over young voters. Air Canada’s pilots agreed to a deal, which saw the company’s stock jump over 3 percent as a result. American  Markets: American...

Market volatility cratered last week as stocks bounced back from one of their worst weeks of the year. With the Fed rates decision looming, we could see volatility pick up this week.

Pfizer's sky-high dividend yield is tempting, but is it sustainable?

These stocks all trade at less than 14 times their expected future profits.

The biotech continues to earn important wins, but is it enough?

These players have had their ups and downs -- but the future looks bright.

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.

They're down but not out, at least not yet.

The time is right to buy all three of these high-yield dividend stocks.

It's not hard to see how these well-seasoned businesses could deliver heaps of passive income to patient investors.

These stocks pay great dividends and could be long-term winners.

These dividend payers could more than double their payouts in the decade ahead.

This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors.

/CNW/ - CareRx Corporation ("CareRx" or "the Company") (TSX: CRRX) today announced that following an extensive executive search process, Suzanne Brand will be...

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading market shares in growing categories.